Benitec Biopharma Ltd is a biotechnology company focused on developing innovative therapeutics leveraging its proprietary DNA-directed RNA interference platform
The company's research aims to address a range of genetic diseases and cancers by utilizing gene silencing technology to inhibit the expression of disease-causing genes. Benitec's approach involves creating treatments that can target specific genetic sequences, thereby offering the potential for durable and long-lasting therapeutic effects. Through its pipeline of drug candidates, Benitec seeks to advance the field of genetic medicine and improve patient outcomes.
Latest clinical data on BB-301 treatment for OPMD. Positive results in swallowing improvement. Benitec Biopharma announces interim findings and $40 million PIPE financing.
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.
U.S. stocks pared some losses toward the end of trading, with the Dow Jones turning higher on Wednesday. The Dow traded up 0.05% to 35,332.35 while the NASDAQ fell 0.46% to 13,820.37. The S&P 500, also fell, dropping, 0.07% to 4,496.29.
Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss.
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining more than 50 points on Monday. The Dow traded up 0.18% to 33,788.05 while the NASDAQ fell 0.61% to 13,410.63. The S&P 500, also fell, dropping, 0.11% to 4,343.41.
